---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-016797"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:04:56.302599+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome Q4 2023 net product revenue $71.5M (+193% YoY); net loss $98.7M; pipeline milestones on track

## Summary
- Total net product revenue $71.5M in Q4 2023 (+193% YoY); full year $204.9M (+309% YoY).
- Auvelity net sales $49.0M in Q4 ($130.1M FY); Sunosi $22.5M Q4 ($74.8M FY, +67% YoY).
- Net loss Q4 $98.7M ($2.08/share) vs $61.2M loss in Q4 2022; FY loss $239.2M ($5.27/share).
- NDA submissions for AXS-07 (migraine) and AXS-14 (fibromyalgia) expected 1H 2024; SYMPHONY topline Q1 2024.
- Cash $386.2M at Dec 31, 2023, up from $200.8M; sufficient to fund ops into cash flow positivity.

## SEC filing metadata
- accession: 0000950170-24-016797
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017024016797/0000950170-24-016797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017024016797/axsm-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-016797
- JSON: https://secwatch.observer/filing/0000950170-24-016797.json
- Plain text: https://secwatch.observer/filing/0000950170-24-016797.txt

## Key facts
- Earnings Releases
  Axsome Therapeutics, Inc. reported the fourth quarter and full year of 2023 results: revenue $71.5 million, net income $(2.08) per share, EPS $(2.08) per share.
  - Period: the fourth quarter and full year of 2023
  - Revenue: $71.5 million
  - Net income: $(2.08) per share
  - EPS: $(2.08) per share
  - Result: reported results
  source text: Total net product revenues were $71.5 million and $204.9 million for the fourth quarter and full year of 2023, representing year-over-year growth of 193% and 309%, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017024016797/0000950170-24-016797-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.